Mizuho Issues Pessimistic Forecast for Nkarta (NASDAQ:NKTX) Stock Price

Nkarta (NASDAQ:NKTX) had its price target lowered by Mizuho from $20.00 to $16.00 in a research report report published on Thursday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other analysts have also recently weighed in on the company. HC Wainwright dropped their price target on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Raymond James raised Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a research report on Wednesday, August 14th. Needham & Company LLC cut their target price on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Finally, Rodman & Renshaw began coverage on shares of Nkarta in a research report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective on the stock. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $15.00.

Nkarta Stock Up 0.4 %

Shares of NASDAQ:NKTX opened at $2.45 on Thursday. The company has a market cap of $172.90 million, a PE ratio of -1.30 and a beta of 0.86. Nkarta has a fifty-two week low of $2.38 and a fifty-two week high of $16.24. The firm has a 50-day simple moving average of $3.79 and a 200 day simple moving average of $5.24.

Institutional Investors Weigh In On Nkarta

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Nkarta by 26.0% during the 1st quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock valued at $21,255,000 after buying an additional 405,753 shares during the period. AQR Capital Management LLC bought a new position in shares of Nkarta in the second quarter valued at approximately $938,000. Federated Hermes Inc. increased its stake in shares of Nkarta by 28,478.7% during the second quarter. Federated Hermes Inc. now owns 135,749 shares of the company’s stock valued at $802,000 after acquiring an additional 135,274 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Nkarta during the second quarter worth approximately $1,489,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Nkarta in the second quarter worth approximately $1,182,000. 80.54% of the stock is currently owned by institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.